Chiasma (CHMA) – Investment Analysts’ Weekly Ratings Updates

Chiasma (NASDAQ: CHMA) recently received a number of ratings updates from brokerages and research firms:

  • 8/1/2019 – Chiasma was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 7/31/2019 – Chiasma is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $11.00 price target on the stock.
  • 7/24/2019 – Chiasma had its “buy” rating reaffirmed by analysts at Brookline Capital Management.
  • 7/23/2019 – Chiasma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. They wrote, “Our $11 price target is based on our DCF valuation. Our DCF model utilizes a terminal rate of decline of 10%, and a WACC-based discount rate of 10.0% (Beta of 1.0, equity risk premium of 5.6%). We assume a 21% tax rate. We apply an 80% risk adjustment to our valuation to account for probability of success for the U.S. and European trials. We currently apply a negative terminal growth rate to account for potential launches by competitors. However, our valuation does not include potential new applications of Chiasma’s TPE platform technology.””
  • 7/10/2019 – Chiasma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
  • 6/28/2019 – Chiasma was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/28/2019 – Chiasma was given a new $11.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 6/6/2019 – Chiasma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. They wrote, “Our $11 price target is based on our DCF valuation. Our DCF model utilizes a terminal rate of decline of 10%, and a WACC-based discount rate of 10.0% (Beta of 1.0, equity risk premium of 5.6%). We assume a 21% tax rate. We apply an 80% risk adjustment to our valuation to account for probability of success for the U.S. and European trials. We currently apply a negative terminal growth rate to account for potential launches by competitors. However, our valuation does not include potential new applications of Chiasma’s TPE platform technology.””

Shares of Chiasma stock traded down $0.07 during trading hours on Friday, reaching $5.07. The stock had a trading volume of 753,577 shares, compared to its average volume of 396,131. The business’s 50 day simple moving average is $7.00. The firm has a market capitalization of $175.09 million, a price-to-earnings ratio of -3.96 and a beta of 1.20. Chiasma Inc has a 1 year low of $1.20 and a 1 year high of $9.25.

Chiasma (NASDAQ:CHMA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). As a group, equities analysts expect that Chiasma Inc will post -1.18 EPS for the current year.

In related news, Director Roni Mamluk sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $6.35, for a total transaction of $63,500.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at approximately $63,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.30% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in Chiasma by 20.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 16,658 shares during the period. Millennium Management LLC bought a new stake in Chiasma in the 4th quarter worth $41,000. Deutsche Bank AG grew its holdings in Chiasma by 27.8% in the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 16,996 shares during the last quarter. Tibra Equities Europe Ltd bought a new stake in Chiasma in the 1st quarter worth $200,000. Finally, New Leaf Venture Partners L.L.C. bought a new stake in Chiasma in the 1st quarter worth $2,080,000. Institutional investors and hedge funds own 62.78% of the company’s stock.

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Chiasma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc and related companies with MarketBeat.com's FREE daily email newsletter.